| Literature DB >> 26450828 |
Vivian Welch1, Mark Petticrew2, Jennifer Petkovic3, David Moher4, Elizabeth Waters5, Howard White6, Peter Tugwell7.
Abstract
BACKGROUND: The promotion of health equity, the absence of avoidable and unfair differences in health outcomes, is a global imperative. Systematic reviews are an important source of evidence for health decision-makers, but have been found to lack assessments of the intervention effects on health equity. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) is a 27 item checklist intended to improve transparency and reporting of systematic reviews. We developed an equity extension for PRISMA (PRISMA-E 2012) to help systematic reviewers identify, extract, and synthesise evidence on equity in systematic reviews. METHODS ANDEntities:
Mesh:
Year: 2015 PMID: 26450828 PMCID: PMC4599721 DOI: 10.1186/s12939-015-0219-2
Source DB: PubMed Journal: Int J Equity Health ISSN: 1475-9276
Checklist of items for reporting equity-focused systematic reviews
| Section | Item | Standard PRISMA Item | Extension for Equity-Focused Reviews |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | Identify equity as a focus of the review, if relevant, using the term equity. |
| Abstract | |||
| Structured summary | 2 | 2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | State research question(s) related to health equity. |
| 2A | Present results of health equity analyses (e.g., subgroup analyses or meta-regression). | ||
| 2B | Describe extent and limits of applicability to disadvantaged populations of interest. | ||
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | Describe assumptions about mechanism(s) by which the intervention is assumed to have an impact on health equity. |
| 3A | Provide the logic model/analytical framework, if done, to show the pathways through which the intervention is assumed to affect health equity and how it was developed. | ||
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to PICOS. | Describe how disadvantage was defined if used as criterion in the review (e.g., for selecting studies, conducting analyses, or judging applicability). |
| 4A | State the research questions being addressed with reference to health equity | ||
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., web address), and, if available, provide registration information including registration number. | |
| Eligibility criteria | 6 | 6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | Describe the rationale for including particular study designs related to equity research questions. |
| 6A | Describe the rationale for including the outcomes (e.g., how these are relevant to reducing inequity). | ||
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | Describe information sources (e.g., health, non-health, and grey literature sources) that were searched that are of specific relevance to address the equity questions of the review. |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Describe the broad search strategy and terms used to address equity questions of the review. |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | List and define data items related to equity, where such data were sought (e.g., using PROGRESS-Plus or other criteria, context). |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., | Describe methods of synthesizing findings on health inequities (e.g., presenting both relative and absolute differences between groups). |
| Risk of bias across studies | 15 | 15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | Describe methods of additional synthesis approaches related to equity questions, if done, indicating which were pre-specified |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Present the population characteristics that relate to the equity questions across the relevant PROGRESS-Plus or other factors of interest. |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot. | |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | Present the results of synthesizing findings on inequities (see 14). |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see item 15). | |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see item 16]). | Give the results of additional synthesis approaches related to equity objectives, if done, (see 16). |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers). | |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | Present extent and limits of applicability to disadvantaged populations of interest and describe the evidence and logic underlying those judgments. |
| 26A | Provide implications for research, practice, or policy related to equity where relevant (e.g., types of research needed to address unanswered questions). | ||
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | |
This checklist should be read in conjunction with the Statement and Explanation and Elaboration document
PICOS participants, interventions, comparisons, outcomes, and study design
Fig. 1Item 3A, Example 1 – Analytic Framework. This is an example of a “funnel of attrition” [41, 42]
Fig. 2Item 3A, Example 2 – Analytic Framework. This is an example of a logic model [43]
Fig. 3Harvest Plot. The ‘harvest plot’ synthesizes and displays the evidence to support possible social gradients in the effects of the intervention [18]
Fig. 4Absolute and Relative Gender Disparity in Stomach Cancer Mortality, 1930–2000 [78]
Example of a summary of findings table that includes an outcome related to health inequity
| The impact of user fees on access to health services in low- and middle-income countries | ||||
|---|---|---|---|---|
| Population: Anyone using any type of health service in low- and middle-income countries. | ||||
| Settings: Burkina Faso, Kenya, Lesotho, Papua New Guinea. | ||||
| Intervention: Introducing or increasing user fees | ||||
| Comparison: No fees | ||||
| Outcomes | Relative change in utilisation1 | Number of studies | Quality of the evidence (GRADE)a | Comments |
| Equity outcome - health utilisation by quartile | N/A | 1 | ⊕ ⊖ ⊖ ⊖ Very low3 | This study where quality improvements were introduced at the same time as user fees found an increase in utilisation for poor groups. The authors did not report the results in a way that the relative change in utilisation could be calculated. |
[93]
Example of a summary of findings table that includes a separate row to show the absolute events for disadvantaged groups
| Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age | ||||||
|---|---|---|---|---|---|---|
| Patient or population: Children aged between 6 months and five years | ||||||
| Intervention: Vitamin A supplementation | ||||||
| Comparison: Placebo or usual care | ||||||
| Outcomes | Illustrative comparative risksa (95 % CI) | Relative effect (95 % CI) | No. of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Diarrhoea-related mortality | Low risk population | RR 0.72; 95 % CI 0.57 to 0.91 | 90,951 (7 studies) | +++O moderate2 | Total number of participants reflects number randomised to studies. The analysis combined cumulative risk and risk per/1000 years follow-up. | |
| 3 per 10001 | 2 per 1000 (2 to 3) | |||||
| Follow-up: 48–104 weeks | Medium risk population | |||||
| 4 per 10001 | 3 per 1000 (2 to 4) | |||||
| High risk population | ||||||
| 9 per 10001 | 6 per 1000 (5 to 8) | |||||
[94]
Example of a separate summary of findings table because of expected differences for disadvantaged population
| Positive | Neutral | Negative | Mixed | Unclear | Total | |
|---|---|---|---|---|---|---|
| Increases in price/tax of tobacco products | 14 | 6 | 4 | 1 | 2 | 27 |
| Smokefree-voluntary, regional, partial | 1 | 1 | 19 | 0 | 4 | 25 |
| Smokefree-compulsory, national, comprehensive | 2 | 9 | 6 | 1 | 4 | 19 |
| Mass media campaigns | 3 | 2 | 5 | 2 | 6 | 18 |
| Mass media campaigns-quitlines and NRT | 5 | 3 | 3 | 0 | 1 | 12 |
| Controls on advertising, promotion and marketing of tobacco | 2 | 7 | 0 | 0 | 9 | |
| Population-level cessation support interventions | 4 | 2 | 0 | 1 | 2 | 9 |
| Setting based interventions(community, workplace, hospital) | 2 | 4 | 1 | 0 | 0 | 7 |
| Multiple policies | 0 | 2 | 0 | 1 | 1 | 4 |
| Total policies | 33 | 36 | 38 | 6 | 17 | 130a |
| Total studies | 31b | 30 | 37 | 6 | 14b | 117 |
Summary equity impact of included studies and policies
aEight studies assessed more than one type of pilocy Dinno 200935 = Smokefree, Price/Tax; Frieden 200549 = Smoke, Price/Tax, Multiple policies; Hawk 99 = Mass Media, Mass Media-quitlines and NRT; Hawkins 2012 53 = Smokefree, Price/Tax
bLevy 200641 = Smokefree, Price/Tax, Mass Media; Nagelhout 201354 = Smokefree, Price/Tax Media; Scaap 200847 = Smokefree, Price/Tax, Controls on advertising, promotion and marketing of tobacco, Multiple policies; Wilson 2010a115 = Controls on advertising, promotion and marketing of tobacco, Mass media-quitlines and NRT
[95]
Terminology related to disadvantaged populations
| To describe the populations who are experiencing inequitable differences we use the term ‘disadvantaged’ although we recognize that this term may not be acceptable to all. In a methodology review of equity assessment, disadvantage was defined in terms of the avoidability or preventability of health inequalities (12 of 34 studies) [ |
| We have chosen to use the term “disadvantaged” for PRISMA-E 2012 because we felt that despite its limitations (e.g., that it may be considered a condescending or paternalistic term), the term “disadvantaged” more clearly defines a population that is experiencing or has experienced health inequities. Whereas vulnerability encompasses a combination of risk, exposure and resilience that do not always lead to health inequities, and other terms such as “marginalized” are too narrowly focused and do not encompass the breadth of settings, contexts and health inequities of interest. |
A note about searching
| Caution should be used when developing the search strategy. Limiting the search using equity-related search terms is not recommended as many studies are not indexed using equity-related terms and potentially relevant studies could be missed. For equity-focused reviews, the search strategy may need to be broadened to reduce the risk of missing potentially included studies. Review authors should plan more time for screening. |